Package 62175-452-32

{"route": ["SUBLINGUAL"], "spl_id": "2f25fc02-629e-4539-82b9-f22f6937d72e", "openfda": {"nui": ["N0000175689", "N0000175685", "N0000175691", "N0000000154"], "unii": ["40D3SCR4GZ", "36B82AMQ7N"], "rxcui": ["351266", "351267"], "spl_set_id": ["14eaa94a-cc8a-4e1e-8cfb-5c976c96c606"], "pharm_class_epc": ["Partial Opioid Agonist [EPC]", "Opioid Antagonist [EPC]"], "pharm_class_moa": ["Partial Opioid Agonists [MoA]", "Opioid Antagonists [MoA]"], "manufacturer_name": ["Lannett Company, Inc."], "is_original_packager": [true]}, "finished": true, "packaging": [{"sample": false, "description": "30 TABLET in 1 BOTTLE (62175-452-32)", "package_ndc": "62175-452-32", "marketing_start_date": "20160919"}], "brand_name": "Buprenorphine and Naloxone", "product_id": "62175-452_2f25fc02-629e-4539-82b9-f22f6937d72e", "dosage_form": "TABLET", "pharm_class": ["Opioid Antagonist [EPC]", "Opioid Antagonists [MoA]", "Partial Opioid Agonist [EPC]", "Partial Opioid Agonists [MoA]"], "product_ndc": "62175-452", "dea_schedule": "CIII", "generic_name": "Buprenorphine and Naloxone", "labeler_name": "Lannett Company, Inc.", "product_type": "HUMAN PRESCRIPTION DRUG", "brand_name_base": "Buprenorphine and Naloxone", "active_ingredients": [{"name": "BUPRENORPHINE", "strength": "2 mg/1"}, {"name": "NALOXONE", "strength": ".5 mg/1"}], "application_number": "ANDA205022", "marketing_category": "ANDA", "marketing_start_date": "20160919", "listing_expiration_date": "20271231"}